Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance for Evaluation of AryoTrust Safety in Iranian HER2-positive Breast Cancer Patients Undergoing Adjuvant Chemotherapy Regimens

NCT06021379 is registered in ClinicalTrials.gov with AryoGen Pharmed Co. as lead sponsor.

NCT NCT06021379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06021379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance for Evaluation of AryoTrust Safety in Iranian HER2-positive Breast Cancer Patients Undergoing Adjuvant Chemotherapy Regimens
Lead sponsor
AryoGen Pharmed Co.
Phase
Observational
Overall status
Completed
Start date
February 22, 2017
Completion date
August 28, 2022
Enrollment
597 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer